MTRNR2L6: A Potential Drug Target and Biomarker (G100463482)

Target Name: MTRNR2L6

NCBI ID: G100463482

MTRNR2L6

MTRNR2L6: A Potential Drug Target and Biomarker

MTRNR2L6, a gene located on chromosome 6, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The MTRNR2L6 gene encodes for a non-coding RNA molecule that has been shown to play a role in regulating the expression of genes involved in cell growth, differentiation, and survival.

Initial Studies

The MTRNR2L6 gene was first identified in a screening experiment for gene expression in human tissue samples using microarray analysis. The gene was shown to be differentially expressed in various tissues, including brain, muscle, and pancreatic tissue, and was associated with the expression of genes involved in cell growth, differentiation, and survival.

To further investigate the functions of MTRNR2L6, researchers used RNA interference (RNAi) technology to knockdown the expression of the gene in human stem cells. The results showed that MTRNR2L6 was involved in the regulation of stem cell self-renewal and expansion, and that inhibition of the gene led to a decrease in stem cell proliferation.

Drug Target Interpretation

The potential drug target for MTRNR2L6 is based on its role in cell growth, differentiation, and survival, as well as its expression in various tissues. Several potential drug candidates have been identified that target MTRNR2L6, including small molecules, peptides, and proteins.

One of the most promising drug candidates is a small molecule inhibitor of MTRNR2L6, which has been shown to inhibit the growth of human cancer cells in a cell culture model. The inhibitor was also shown to decrease the expression of MTRNR2L6 in human stem cells, suggesting that it may have a potential impact on stem cell proliferation.

Biomarker Potential

MTRNR2L6 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The MTRNR2L6 gene has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer.

In addition, MTRNR2L6 has also been shown to be involved in the regulation of cellular processes that are involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Conclusion

MTRNR2L6 is a gene that has the potential to be a drug target for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The MTRNR2L6 gene has been shown to play a role in regulating the expression of genes involved in cell growth, differentiation, and survival, and has been identified as a potential drug target using small molecule inhibitors and RNA interference technology. Further research is needed to determine the full extent of MTRNR2L6's role in disease and to develop safe and effective drugs that target this gene.

Protein Name: MT-RNR2 Like 6 (pseudogene)

Functions: Plays a role as a neuroprotective and antiapoptotic factor

The "MTRNR2L6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTRNR2L6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets